207557-33-3

Basic information

• Product Name: 2-Pyrrolidinecarbonitrile, 1-(bromoacetyl)-, (2S)- (9CI)
• Synonyms: 2-Pyrrolidinecarbonitrile, 1-(bromoacetyl)-, (2S)- (9CI)
• CAS NO: 207557-33-3
• Molecular Formula: C₇H₉BrN₂O
• Molecular Weight: 217.06316
• Product Categories: ACETYLHALIDE
• Mol File: 207557-33-3.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Pyrrolidinecarbonitrile, 1-(bromoacetyl)-, (2S)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyrrolidinecarbonitrile, 1-(bromoacetyl)-, (2S)- (9CI)(207557-33-3)
• EPA Substance Registry System: 2-Pyrrolidinecarbonitrile, 1-(bromoacetyl)-, (2S)- (9CI)(207557-33-3)

Safety Data

• Hazardous Substances Data: 207557-33-3(Hazardous Substances Data)

Upstream product

• 598-21-0 2-Bromoacetyl bromide 
• 7531-52-4 L-prolinamide 
• 204387-53-1 (2S)-pyrrolidine-2-carbonitrile 
• 253309-37-4 (S)-1-(2-bromoacetyl)pyrrolidine-2-carboxamide 

Downstream Products

• 934972-77-7 3-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-3-methyl-N-[(1S,2R)-2-(3-chlorophenyl)cyclopropyl]butanamide 

Relevant articles and documents

DIPEPTIDYL PEPTIDASE-IV INHIBITORS

The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.

1-[2-[(5-Cyanopyridin-2-yl)amino]-ethylamino]acetyl-2-(S)-pyrrolidine -carbonitrile: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

Dipeptidyl peptidase IV (DPP-IV) inhibition has the potential to become a valuable therapy for type 2 diabetes We report the first use of solid-phase synthesis in the discovery of a new DPP-IV inhibitor class and a solution-phase synthesis that is practical up to the multikilogram scale. One compound NVP-DPP728 (2), is profiled as a potent, selective, and short-acting DPP-IV inhibitor that has excellent oral bioavailability and potent antihyperglycemic activity.